Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
R Comenzo
Observed names:
Comenzo, RL,
Rl Comenzo
OpenAlex ID:
A5074859256
Works
4
Awards
1
Prospective Evaluation of the Utility of the Serum Free Light Chain Assay (FLC), Clonal Ig VL Gene Identification and Troponin I Levels in a Phase II Trial of Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic AL Amyloidosis
2004
·
Rl Comenzo
, P. Zhou
, et al.
·
CRC Press eBooks
·
2
Subcutaneous Daratumumab (Dara) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival (OS) and Final Major Organ Deterioration Progression-Free Survival Results From the Phase 3 Andromeda
2025
·
Carpinteiro, A
, Kastritis, E
, et al.
·
UCL Discovery (University College London)
Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic Al Amyloidosis: Interim Report of a Phase II Trial
2004
·
P Zhou
, M Fleisher
, et al.
·
CRC Press eBooks
Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic AL Amyloidosis: Interim Report of a Phase II Trial
2004
·
Rl Comenzo
, P. Zhou
, et al.
·
CRC Press eBooks
Show more works
View as search
Works count:
4
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type